Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

breast cancer, as determined by an FDA-approved test, that has progressed on 1 or more endocrine therapies in the metastatic setting. Enhertu is a HER2-directed antibody and topoisomerase inhibitor ...

in the overall trial population of patients with chemotherapy-naive HER2-low or HER2-ultralow metastatic breast cancer. Patients randomly assigned to Enhertu had a median progression-free survival ...

More common side effects in people receiving Enhertu for breast cancer, NSCLC, or solid tumors include: Mild side effects that may occur from receiving Enhertu may vary depending on the condition ...

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

Trastuzumab deruxtecan (Enhertu; AstraZeneca ... treatment of adults with unresectable or metastatic HER2-positive breast cancer who received two or more prior anti-HER2-based regimens; adults ...